Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea
Kyung‐Wook Jo, Mi-Hye Kim, Ye‐Jee Kim, Hyun-Kyung Lee, Hyun Kuk Kim, Doosoo Jeon, Jiwon Lyu, Hye Kyeong Park, et al. (14 authors)
Antimicrobial Agents and Chemotherapy · 2019-09
Abstract
No studies have investigated whether the discontinuation of ethambutol (EMB) based on susceptibility to isoniazid and rifampin, as determined by the GenoType MTBDRplus assay, would be appropriate. We aimed to determine the feasibility of discontinuing EMB before the end of the intensive phase of treatment based on the results of the MTBDRplus assay in patients with pulmonary tuberculosis (PTB).
MeSH terms
- Discontinuation
- Ethambutol
- Medicine
- Multicenter study
- Tuberculosis
- Genotype
- Internal medicine
- Multicenter trial
- Pulmonary tuberculosis
- Randomized controlled trial
- Rifampicin